Better Targets, Better Antibodies,
Better Outcomes
We build precision antibodies to treat cancer patients.
Aclys builds antibodies specifically designed for precision applications. Precision oncology provides significant benefits including, higher efficacy, smaller trial size, lower trial cost, faster approval, and five-fold higher likelihood of FDA approval. Aclys is bringing precision to antibodies.
The Problem
“a lack of drugs is the main barrier to implementing precision medicine”, Quantifying the Benefits of Precision Oncology
Sequencing of tumor biopsies is rapidly becoming the standard of care. While this type of profiling can identify actionable gene mutations or target gene expression, care is currently limited by a lack of targeted therapeutics.
Many drug developers are using these data to identify people more likely to respond to their therapies. We are using patient data to identify treatment gaps and design new-to-world therapies built for high success rates.
Our Solution
Aclys builds antibodies optimized for precision development. Aclys uses molecular profiling data from tens of thousands of cancer patients to build antibody-based precision therapeutics.
The resultant therapeutics are designed to have greater efficacy and safety, enable highly powered clinical trials with 1/10th the enrollees and cost, and have a much faster path to market than industry averages.
